Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • VistaGen Therapeutics, Inc. (VSTA) Opens The Door To Multiple Opportunities 0 comments
    Jul 8, 2013 6:36 PM | about stocks: VSTA

    A great technology is one that not only fills important needs, but one that can be applied in more than one way to meet important needs. It gives the developer important flexibility in determining how to best address the marketplace, allowing them to avoid approaches that may be technically feasible but which involve low-margins or other problems. It can be the difference between a good idea that leads directly to financial success or a good idea that doesn't get off the ground.

    VistaGen Therapeutics, a California-based biotech company, has developed such a technology, providing them multiple options for monetization. Using their proprietary stem cell technology, VistaGen has created their Human Clinical Trials in a Test Tube bioassay platform, allowing researchers to test new drug candidates against actual heart and liver cells right in the lab, well before going to the expense of further development. The advantage is the early identification of potential heart or liver toxicity issues prior to spending enormous amounts of money taking a candidate through clinical trials or even all the way to market.

    It's a technology that gives VistaGen more than one approach to the market. The technology could be the basis for a proprietary screening service, potentially saving the pharmaceutical industry millions or even billions of dollars in misdirected investments. It could also represent a major purchase target, making VistaGen itself highly attractive as a possible takeover. But it's a technology that also gives VistaGen the ability to take earlier drug candidates, previously shelved due to liver or heart toxicity issues, and rescue them, using their unique testing platform to modify the drugs, generating their own high-margin pipeline of safe drug candidates. Even moderate success at such a pipeline would be extraordinarily profitable.

    For more information, visit www.vistagen.com

    Please see disclaimer on the MissionIR website
    http://www.missionir.com/disclaimer.html

    Stocks: VSTA
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.